REGN|Regeneron Pharmaceuticals Inc|Price:759.180|Chg%:4.16

More Details of Regeneron Pharmaceuticals Inc Company

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Regeneron Pharmaceuticals Inc Info



Ticker SymbolREGN

Company nameRegeneron Pharmaceuticals Inc

IPO dateApr 02, 1991

CEOSchleifer (Leonard S)

Number of employees15106

Security typeOrdinary Share

Fiscal year-endApr 02

Address777 Old Saw Mill River Road

CityTARRYTOWN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code10591

Phone17813705000

Websitehttps://www.regeneron.com/

Ticker SymbolREGN

IPO dateApr 02, 1991

CEOSchleifer (Leonard S)

Company Executives of Regeneron Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

21.78K

+2035.00%

Mr. Arthur F. (Art) Ryan

Independent Director

17.81K

+155.00%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.49K

+119.00%

Dr. Michael S. Brown, M.D.

Independent Director

12.77K

+155.00%

Name

Name/Position

Position

Shareholding

Change

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Other

462.20M

12.31%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Other

462.20M

12.31%

Shareholding Stats

Updated: Sun, Nov 16

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Other

74.18%

Shareholders

Proportion

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Other

74.18%

Shareholder Types

Shareholders

Proportion

Investment Advisor

45.29%

Investment Advisor/Hedge Fund

31.13%

Hedge Fund

5.04%

Pension Fund

2.77%

Research Firm

2.72%

Bank and Trust

2.20%

Individual Investor

2.07%

Sovereign Wealth Fund

1.23%

Insurance Company

0.20%

Other

7.36%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

2674

93.48M

90.51%

-2.18M

2025Q3

2596

94.26M

91.26%

-4.21M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

9.00M

8.71%

-376.36K

-4.02%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.46M

5.29%

-204.21K

-3.60%

Sep 30, 2025

State Street Investment Management (US)

4.69M

4.54%

-140.78K

-2.91%

Sep 30, 2025

Dodge & Cox

4.55M

4.41%

+724.56K

+18.94%

Sep 30, 2025

JP Morgan Asset Management

2.95M

2.85%

+130.73K

+4.64%

Sep 30, 2025

Geode Capital Management, L.L.C.

2.54M

2.46%

+70.84K

+2.87%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

2.32M

2.24%

+133.61K

+6.12%

Dec 31, 2025

Putnam Investment Management, L.L.C.

2.15M

2.08%

+117.43K

+5.78%

Sep 30, 2025

Capital World Investors

2.00M

1.93%

+32.35K

+1.65%

Sep 30, 2025

Loomis, Sayles & Company, L.P.

1.98M

1.92%

+38.38K

+1.98%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

ProShares Ultra Nasdaq Biotechnology

6.6%

Invesco Nasdaq Biotechnology ETF

6.55%

Amplify Weight Loss Drug & Treatment ETF

6.4%

iShares Biotechnology ETF

5.9%

Simplify Health Care ETF

5.54%

VanEck Biotech ETF

5.51%

Invesco Biotechnology & Genome ETF

5.4%

iShares Genomics Immunology and Healthcare ETF

4.97%

First Trust NASDAQ Pharmaceuticals ETF

4.36%

First Trust NYSE Arca Biotechnology Index Fund

3.88%

ProShares Ultra Nasdaq Biotechnology

Proportion6.6%

Invesco Nasdaq Biotechnology ETF

Proportion6.55%

Amplify Weight Loss Drug & Treatment ETF

Proportion6.4%

iShares Biotechnology ETF

Proportion5.9%

Simplify Health Care ETF

Proportion5.54%

VanEck Biotech ETF

Proportion5.51%

Invesco Biotechnology & Genome ETF

Proportion5.4%

iShares Genomics Immunology and Healthcare ETF

Proportion4.97%

First Trust NASDAQ Pharmaceuticals ETF

Proportion4.36%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.88%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Jan 30, 2026

REGN.NB Interim Cash Dividend of gross USD 0.94 paid on Mar 05, 2026 going ex on Feb 20, 2026

Feb 20, 2026

Mar 05, 2026

Feb 20, 2026

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data